{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:39:57Z","timestamp":1777934397166,"version":"3.51.4"},"reference-count":35,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Oral oncolytics have improved survival in hematological cancers like chronic myeloid leukemia, chronic lymphocytic leukemia\/small lymphocytic lymphoma, and multiple myeloma; however, it is unclear of the extent to which initiating these treatments might impact adherence to oral therapies for pre-existing comorbid chronic conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults diagnosed with and prescribed oral oncolytics for chronic myeloid leukemia, chronic lymphocytic leukemia\/small lymphocytic lymphoma, or multiple myeloma between 2013 and 2016 and with continuous eligibility six months before and after oral oncolytic initiation were identified from the Truven Health MarketScan databases. Among those identified, patients with pre-existing diabetes, hypertension, and\/or hyperlipidemia with \u22651 fill for oral comorbid therapies were selected. Adherence to oral oncolytics and comorbid therapies was measured using the proportion of days covered metric. Wilcoxon signed-rank tests assessed changes in adherence for comorbid therapies after initiation of an oral oncolytic. Unadjusted difference-in-difference models assessed the impact of adherence to oral oncolytics on changes in adherence to comorbid therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Significant reductions in adherence after oncolytic initiation were observed across the comorbid therapies and were highest for patients taking lipid-lower agents (10.7\u201315.6%). Unadjusted difference-in-difference models revealed consistent and significantly lower reductions in adherence for those taking antihypertensives (chronic myeloid leukemia: p\u2009=\u20090.03; chronic lymphocytic leukemia\/small lymphocytic lymphoma: p\u2009=\u20090.007; multiple myeloma: p\u2009=\u20090.09) and adherent to oral oncolytics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Initiation of oral oncolytics may negatively impact adherence to oral therapies for chronic comorbid conditions, necessitating the need for medication management strategies to help patients adhere to their entire medication regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155219875206","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T00:33:10Z","timestamp":1569976390000},"page":"835-845","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of oral oncolytic initiation on medication adherence for pre-existing comorbid chronic conditions"],"prefix":"10.1177","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0898-959X","authenticated-orcid":false,"given":"Ankur A","family":"Dashputre","sequence":"first","affiliation":[{"name":"Institute for Health Outcomes and Policy, College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"S Gatwood","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jillian","family":"Schmidt","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Tennessee Health Science Center, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Gatwood","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Tennessee Health Science Center, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,10,1]]},"reference":[{"key":"bibr1-1078155219875206","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21349"},{"key":"bibr2-1078155219875206","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21332"},{"key":"bibr3-1078155219875206","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21442"},{"key":"bibr4-1078155219875206","unstructured":"Noone A, Howlader N, Krapcho M, et\u00a0al. SEER Cancer Statistics Review, 1975-2015. National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/csr\/1975_2015\/, based on November 2017 SEER data submission, posted to the SEER web site, (2018, accessed 10 February 2019)."},{"key":"bibr5-1078155219875206","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9542-z"},{"key":"bibr6-1078155219875206","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.09.008"},{"key":"bibr7-1078155219875206","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14785"},{"key":"bibr8-1078155219875206","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1105202"},{"key":"bibr9-1078155219875206","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(98)80139-2"},{"key":"bibr10-1078155219875206","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.22.2880"},{"key":"bibr11-1078155219875206","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2011.10.002"},{"key":"bibr12-1078155219875206","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2424-2"},{"key":"bibr13-1078155219875206","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3660"},{"key":"bibr14-1078155219875206","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1291"},{"key":"bibr15-1078155219875206","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.495"},{"key":"bibr16-1078155219875206","first-page":"e22","volume":"15","author":"Saini SD","year":"2009","journal-title":"Am J Manag Care"},{"key":"bibr17-1078155219875206","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016982"},{"key":"bibr18-1078155219875206","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2014.02.001"},{"key":"bibr19-1078155219875206","first-page":"e208","volume":"23","author":"Curtis SE","year":"2017","journal-title":"Am J Manag Care"},{"key":"bibr20-1078155219875206","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S15619"},{"key":"bibr21-1078155219875206","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-018-0716-6"},{"key":"bibr22-1078155219875206","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3971"},{"key":"bibr23-1078155219875206","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2014.003046"},{"key":"bibr24-1078155219875206","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3497-8"},{"key":"bibr25-1078155219875206","unstructured":"Truven Health Analytics IBM Watson Health. The Truven Health MarketScan Databases for Health Services Research, https:\/\/truvenhealth.com\/portals\/0\/assets\/2017_MarketScan_Databases_Health_Services_Researchers.pdf (2017, accessed 30 October 2018)."},{"key":"bibr26-1078155219875206","unstructured":"National Cancer Institute. NCI Comorbidity Index Overview, https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/comorbidity.html, (accessed 21 November 2018)."},{"key":"bibr27-1078155219875206","unstructured":"PQA Measure Specifications. Proportion of Days Covered (PDC), www.ncpanet.org\/pdf\/adherence_list.pdf (accessed 21 November 2018)."},{"key":"bibr28-1078155219875206","doi-asserted-by":"publisher","DOI":"10.1016\/j.copsyc.2015.03.004"},{"key":"bibr29-1078155219875206","doi-asserted-by":"publisher","DOI":"10.1007\/s10865-007-9147-y"},{"key":"bibr30-1078155219875206","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200825100-00008"},{"key":"bibr31-1078155219875206","first-page":"183","volume":"6","author":"Scott Leslie R","year":"2014","journal-title":"Am J Pharm Benefit"},{"key":"bibr32-1078155219875206","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2008.14.6.553"},{"key":"bibr33-1078155219875206","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0002"},{"key":"bibr34-1078155219875206","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.307"},{"key":"bibr35-1078155219875206","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e318032937e"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219875206","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155219875206","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219875206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:21:53Z","timestamp":1777688513000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155219875206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1177\/1078155219875206"],"URL":"https:\/\/doi.org\/10.1177\/1078155219875206","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,1]]}}}